Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 7Other hematologic neoplasm 5Lymphoid 2Classical hematology 2Plasma cell 1Other neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Precancerous Conditions 1Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Whole-Body Irradiation 3Methotrexate 3Cyclophosphamide 3Tacrolimus 2Sirolimus 2Mycophenolic Acid 2Melphalan 2Etoposide 2Cyclosporine 2Busulfan 2Antilymphocyte Serum 2ruxolitinib 1Tetradecanoylphorbol Acetate 1Phenytoin 1Oxycodone 1Music Therapy 1Moxifloxacin 1Morphine 1Methadone 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Fentanyl 1Early Intervention, Educational 1Ciprofloxacin 1CPI-0610 1Asian ginseng 1Amoxicillin-Potassium Clavulanate Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × ruxolitinib × Other neoplasm × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡